Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. - Wikidata - awgldk - TriplyDB

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

http://www.wikidata.org/entity/Q36920433

about

The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapy The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Idelalisib in the management of lymphoma.Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.Targeting of B-cell receptor signalling in B-cell malignancies.Targeting indolent non-Hodgkin lymphoma.Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.Current Treatment of Chronic Lymphocytic Leukemia.IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.Syk inhibitors in clinical development for hematological malignancies.Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.The PI3K Pathway in Human Disease.CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies.Title: Rituximab: A Benchmark in the Development of Chemotherapy-free Treatment Strategies for Follicular Lymphomas.The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis.Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?The future of kinase inhibitors for DLBCL?Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date

P2860

Q28072397-BEECA2E8-C7A9-4AB4-A7A7-1DFB937825F9 Q29248893-95AFDA5E-EA8B-44EF-B4EB-47FD0B2C8D27 Q30243968-E1FE0EA7-7AE1-48D4-AC9D-01DFEEE634ED Q34529311-D03D2840-D1DA-40A9-92A5-31498F55B95E Q37701548-2C74C6AE-860D-4DDA-AA62-AED4D4907B43 Q38685006-802DCDA8-4DD2-4971-B18A-C0D40493AC39 Q38691282-5E76A87E-5651-4B11-9458-72F3939065EA Q38744922-24D1017B-9AEF-4636-8FBC-2DD2CF109DC7 Q38917848-A9666FC3-2658-4EC8-9A37-4EBBCF80670D Q38984735-33F3982E-B581-4B1D-8455-48AC2E3A97A3 Q39098904-35FA7DD6-A266-4249-BAE6-62A5142BD2BB Q39129372-9C5F2318-D12E-4086-B13F-AD778624F2DB Q39150343-DF83F80D-1775-4D34-A876-57153478F6A4 Q39227773-ABAB189C-D62B-4B82-AE6B-6328250BD8A2 Q39472422-18F9AE00-8082-4FC1-A05B-62159D194A24 Q42011012-A3FA5B9C-E77D-4990-BE19-AD61833AF9EA Q46074725-B0D795B7-8E34-473E-BEEF-52BC414CE7DC Q46546002-7080C5ED-74C8-4B24-A9A1-94D6CC1B1A7D Q47109026-0026805A-B5DE-4C6A-8806-BA9A34F62058 Q47163960-9101F55A-D51E-477D-B849-A0B5E822F67F Q47300115-20F83232-7690-4FA0-9659-0E1C7A22C94F Q47365893-BB320DF1-A309-456C-95FC-48A905B204E6 Q48120395-7DBFDB22-1228-4D9B-9D2E-2DE02F1D840B Q49226138-6AB11223-271A-477A-892E-21AC377C7E37 Q52656283-1859F9F5-8DAD-4EDD-9027-7CB07DC55030 Q52812536-850DF61B-08E9-45E2-9131-F886F398A53E Q54978376-A9BB638C-4271-4172-B778-9204A74296D7 Q54979889-871E1D54-71A2-4594-BAE6-4515BADD8996 Q58729853-EA604114-9A29-4797-A2ED-F15CE792D214 Q58785964-4BC1475F-6D19-4456-8345-5CBBA00B816D

P2860

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.

http://www.wikidata.org/entity/Q36920433

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Phase 2 study of idelalisib an ...... lapsed refractory CLL and NHL.

@en

type

label

Phase 2 study of idelalisib an ...... lapsed refractory CLL and NHL.

@en

prefLabel

Phase 2 study of idelalisib an ...... lapsed refractory CLL and NHL.

@en

P1433

Q36920433-2CF31684-D861-4B34-95B1-C53A175F4373

P1476

Q36920433-6D5EA2AB-A0BD-406D-BAE6-D11B4A0C75D3

P2093

Q36920433-012C41CE-9420-4878-91A6-88D46770919B

Q36920433-053E2DF7-585F-42E6-9412-7A5B1BB2A615

Q36920433-21083AA7-EA49-4D92-8D8A-A5E3891BE54B

Q36920433-213E97BF-84F5-463B-8A7E-F15A7DCB0BD7

Q36920433-25714FCA-EB28-40C7-A028-66F4F1D7CB5B

Q36920433-39271AFC-0A63-4D86-B74B-A621668EBEC5

Q36920433-4AEFBBDB-FE38-4E14-A87C-2F789EC1DC1C

Q36920433-56FAB97A-15D6-4782-AC21-A575CD7CBF69

Q36920433-58008FE9-23BC-4CB6-A3E5-95D61A8ED334

Q36920433-598599BB-BDE2-40FB-A096-00CFA5CD9329

P2860

Q36920433-0628D8C0-9C1C-448B-AC8D-F08AA4E7AE21

Q36920433-0E45D579-7C05-460B-B292-5FE86A60C6BB

Q36920433-21705E19-9FBE-46D4-B955-14306E20D6CB

Q36920433-3AA3B2D2-8211-40D0-A8E0-8E2F7947800C

Q36920433-3D3C48F5-0E03-4F8B-A3DE-2BAEBC24954A

Q36920433-56408797-EA81-4F54-B399-0F104AE20DEE

Q36920433-608D4CFF-F03D-4AA7-B7AA-A2C689FB6A85

Q36920433-74721CCA-22C3-4083-9B67-061F9CA21C9E

Q36920433-853966E4-9A34-4EC6-923D-C940029E38F2

Q36920433-9E5A1625-08EB-4A46-99D7-BA2B22C9F44B

P304

Q36920433-A3F17CB4-A881-41CB-B2FA-0B07415C9151

P31

Q36920433-6A90B629-6D2D-4219-BC7F-A74B5F954015

P356

Q36920433-65C99B45-B1C9-4538-BCA4-26B26A8AC7AC

P407

Q36920433-956F1165-7BC3-4A29-B735-CD46DEB101D3

P433

Q36920433-DB7F71CB-B58D-4551-B080-1F6B9CEBE18A

P478

Q36920433-0EA46119-2074-46E4-BA82-8FFEB9A0FCD5

P50

Q36920433-B2140710-A7B6-4772-B401-FB45ED8AB38C

P577

Q36920433-C45639F3-4545-4EF5-84B2-ED7AC8FC5996

P698

Q36920433-C5771F19-D9D6-4E92-97DB-6C12D5CEB3F1

P932

Q36920433-0989082D-C603-4F97-B1BA-D0B3197110C7

P356

BLOOD-2015-12-683516

P1433

P1476

Phase 2 study of idelalisib an ...... lapsed refractory CLL and NHL.

@en

P2093

Adarsh Joshi

http://www.w3.org/2001/XMLSchema#string

Andre K D Liem

http://www.w3.org/2001/XMLSchema#string

Anita Reddy

http://www.w3.org/2001/XMLSchema#string

Bruce D Cheson

http://www.w3.org/2001/XMLSchema#string

Daniel R Greenwald

http://www.w3.org/2001/XMLSchema#string

Esteban Abella-Dominicis

http://www.w3.org/2001/XMLSchema#string

Gene B Saylors

http://www.w3.org/2001/XMLSchema#string

Hank Lee

http://www.w3.org/2001/XMLSchema#string

Jing Hu

http://www.w3.org/2001/XMLSchema#string

Jonathan W Friedberg

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Sirolimus-associated pulmonary toxicity.

Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis.

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

P304

2411-2415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-12-683516

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26968534

http://www.w3.org/2001/XMLSchema#string

P932

4874222

http://www.w3.org/2001/XMLSchema#string